Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 6,990,000 shares, a growth of 8.7% from the June 15th total of 6,430,000 shares. Based on an average trading volume of 638,600 shares, the days-to-cover ratio is currently 10.9 days.
Celldex Therapeutics Trading Down 3.0 %
CLDX traded down $1.20 during trading on Wednesday, hitting $38.78. The company’s stock had a trading volume of 540,883 shares, compared to its average volume of 787,414. The firm’s 50 day moving average price is $36.74 and its 200-day moving average price is $39.20. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. As a group, analysts forecast that Celldex Therapeutics will post -2.39 EPS for the current year.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Celldex Therapeutics
Insider Transactions at Celldex Therapeutics
In other news, SVP Diane C. Young sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the sale, the senior vice president now owns 2,115 shares of the company’s stock, valued at approximately $74,574.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Diane C. Young sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the sale, the senior vice president now owns 2,115 shares of the company’s stock, valued at approximately $74,574.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Margo Heath-Chiozzi sold 38,719 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $34.07, for a total value of $1,319,156.33. Following the sale, the senior vice president now directly owns 7,094 shares in the company, valued at approximately $241,692.58. The disclosure for this sale can be found here. Insiders have sold 266,332 shares of company stock valued at $9,155,821 in the last quarter. 3.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Celldex Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in CLDX. Strs Ohio increased its holdings in shares of Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 1,300 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics during the 1st quarter worth $147,000. CANADA LIFE ASSURANCE Co boosted its position in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the period. Aigen Investment Management LP purchased a new stake in Celldex Therapeutics during the 4th quarter worth $251,000. Finally, Panoramic Investment Advisors LLC purchased a new stake in Celldex Therapeutics during the 4th quarter worth $258,000.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
- Five stocks we like better than Celldex Therapeutics
- Trading Halts Explained
- Real Estate Stock Signals a Boom in Manufacturing Activity
- What is Insider Trading? What You Can Learn from Insider Trading
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.